Prognostic Markers in Node-Negative Breast Cancer: A Prospective Study

Cytometry Part B - Clinical Cytometry

Volumn 59, Issue 1, 2004, Pages 24-31

  Kute, Timothy E ^a   Russell, G B ^a   Zbieranski, N ^a   Long, R ^a   Johnston, S ^a   Williams, H ^a   Stackhouse, C ^a   Wilkins, L ^a   Evans, I ^b   Berry, P ^a   Rimmer, K ^c   Tucker, E ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

^c Forsythe Memorial Hospital   (United States)

^d High Point Regional Hospital   (United States)

Author keywords

Cathepsin D; Ploidy; S phase; Steroid receptors

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; RACE;

EID: 2342575660     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.20003     Document Type: Article

References (21)

1. Adjuvant therapy for breast cancer - National Institutes of Health Consensus Development Conference, November 3, 2000. 17 p.
2. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-978.
3. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute TE, Merkel D. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Breast Cancer Res Treat 1993;28:55-59.
4. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989;63: 181-187.
5. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Randian MR, Harrington D, Clark GM, McQuire WL. DNA ploidy, s-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 1993;28:9-20.
6. Fidler IJ. Tumor heterogeneity and biology of cancer invasion and metastasis. Cancer Res 1978;38:2651-2660.
7. Kute TE, Shao ZM, Sugg NK, Long RT, Russell GB, Case D. Cathepsin D and other markers as prognostic indicators for node negative breast cancer patients. Cancer Res 1992;52:5198-5203.
8. Kute TE, Grondahl-Hansen J, Shao S-M, Long R, Russell G, Brunner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 1998;47: 9-16.
9. Bagwell CB. Flow cytometry data analysis in clinical cytometry. In: Bauer K, Shankey V, editors. Clinical flow cytometry. Theoretical aspects of flow cytometry data analysis. New York: Velez-Liss; 1992. p 41-61.
10. Kute TE, Quadri Y, Muss H, Zbieranski N, Cirrincione C, Berry DA, Barcos M, Thor AP, Liu E, Koerner F, Henderson IC. Flow cytometry in node-positive breast cancer: cancer and leukemia group B protocol 8869. Cytometry 1995;22:297-306.
11. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
12. Cox D. Regression models and life tables (with discussion). J R Stat Soc Ser B Stat Methodol 1972;34:87-202.
13. Bagwell CB, Clark GM, Spyratos F, Chassevent A, Bendahl PO, Stal O, Killander D, Jourdan ML, Romain S, Hunsberger B, Wright S, Baldetorp B. DNA and cell cycle analysis as prognostic indicators in breast tumors revisited. Clin Lab Med 2001;21:875-895.
14. Ravdin PM, de Moor CA, Hilsenbeck SG, Samoszuk MK, Vendely PM, Clark GM. Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. Cancer Lett 1997; 116:177-183.
15. Chassevent A, Jourdan ML, Romain S, Descotes R, Colonna M, Martin PM, Bolla M, Spyratos F. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study. Clin Cancer Res 2001;7:909-917.
16. Bryant J, Fisher B, Gunduz N, Costantino JP, Emir B. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat, 1998;51:239-253.
17. Sigurdsson H, Baldetorp B, Bord A, Dalberg M, Ferno M, Killander D, Olsson H. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990;332:1045-1053.
18. Wenger CR, Clark GM. S-phase fraction and breast cancer - a decade of experience. Breast Cancer Res Treat 1988;51:255-265.
19. Michels JJ, Duigou F, Marnay J. Flow cytometry in primary beast carcinomas. Prognostic impact of proliferative activity. Breast Cancer Res Treat 2000;62:117-126.
20. Polychemotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-942.
21. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351:1451-1467.